JP2010514725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514725A5 JP2010514725A5 JP2009543441A JP2009543441A JP2010514725A5 JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5 JP 2009543441 A JP2009543441 A JP 2009543441A JP 2009543441 A JP2009543441 A JP 2009543441A JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5
- Authority
- JP
- Japan
- Prior art keywords
- methanone
- methanesulfonyl
- trifluoro
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- Fluoro-5-trifluoromethyl-pyridin-2-yl Chemical group 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 12
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 238000002329 infrared spectrum Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- GWTMPNXPVMDUTM-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CN=CC(C(F)(F)F)=C1 GWTMPNXPVMDUTM-UHFFFAOYSA-N 0.000 claims 1
- VFDFJCYNWDITDA-ZETCQYMHSA-N 5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxybenzaldehyde Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C=O VFDFJCYNWDITDA-ZETCQYMHSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 | ||
| EP06127269.6 | 2006-12-28 | ||
| PCT/EP2007/064104 WO2008080821A1 (en) | 2006-12-28 | 2007-12-18 | Crystalline forms glyt1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514725A JP2010514725A (ja) | 2010-05-06 |
| JP2010514725A5 true JP2010514725A5 (OSRAM) | 2010-12-02 |
| JP4799666B2 JP4799666B2 (ja) | 2011-10-26 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543441A Active JP4799666B2 (ja) | 2006-12-28 | 2007-12-18 | 結晶形態のｇｌｙｔ１ |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (OSRAM) |
| EP (1) | EP2114405B1 (OSRAM) |
| JP (1) | JP4799666B2 (OSRAM) |
| KR (1) | KR101130146B1 (OSRAM) |
| CN (1) | CN101573114A (OSRAM) |
| AR (1) | AR064545A1 (OSRAM) |
| AU (1) | AU2007341356B2 (OSRAM) |
| BR (1) | BRPI0720829B8 (OSRAM) |
| CA (1) | CA2673667A1 (OSRAM) |
| CL (1) | CL2007003830A1 (OSRAM) |
| CO (1) | CO6190613A2 (OSRAM) |
| CR (1) | CR10846A (OSRAM) |
| CY (1) | CY1116350T1 (OSRAM) |
| DK (1) | DK2114405T3 (OSRAM) |
| EC (1) | ECSP099471A (OSRAM) |
| ES (1) | ES2535040T3 (OSRAM) |
| HR (1) | HRP20150573T1 (OSRAM) |
| HU (1) | HUE025032T2 (OSRAM) |
| MA (1) | MA31029B1 (OSRAM) |
| MX (1) | MX2009006859A (OSRAM) |
| MY (1) | MY188367A (OSRAM) |
| NO (1) | NO342150B1 (OSRAM) |
| NZ (1) | NZ577502A (OSRAM) |
| PE (1) | PE20081556A1 (OSRAM) |
| PL (1) | PL2114405T3 (OSRAM) |
| PT (1) | PT2114405E (OSRAM) |
| RS (1) | RS53910B1 (OSRAM) |
| RU (1) | RU2463295C2 (OSRAM) |
| SI (1) | SI2114405T1 (OSRAM) |
| TW (1) | TWI388552B (OSRAM) |
| UA (1) | UA100232C2 (OSRAM) |
| WO (1) | WO2008080821A1 (OSRAM) |
| ZA (1) | ZA200904423B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573114A (zh) | 2006-12-28 | 2009-11-04 | 弗·哈夫曼-拉罗切有限公司 | 结晶形式glyt1 |
| WO2010099323A1 (en) * | 2009-02-26 | 2010-09-02 | Thar Pharmaceuticals, Inc. | Crystalization of pharmaceutical compounds |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| EA201401312A1 (ru) * | 2012-05-25 | 2015-09-30 | Басф Се | КРИСТАЛЛИЧЕСКАЯ ФОРМА В 1,5-ДИМЕТИЛ-6-ТИОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ИНИЛ)-3,4-ДИГИДРО-2Н-БЕНЗО[b][1,4]ОКСАЗИН-6-ИЛ)-1,3,5-ТРИАЗИНАН-2,4-ДИОНА |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| WO2022014396A1 (ja) * | 2020-07-13 | 2022-01-20 | 日本碍子株式会社 | 精製方法 |
| JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| JP2024520391A (ja) * | 2021-05-27 | 2024-05-24 | ディスク・メディシン・インコーポレイテッド | ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| CN101573114A (zh) | 2006-12-28 | 2009-11-04 | 弗·哈夫曼-拉罗切有限公司 | 结晶形式glyt1 |
-
2007
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514725A5 (OSRAM) | ||
| RU2009124113A (ru) | Кристаллические формы glyt1 | |
| JP2009040783A5 (OSRAM) | ||
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| CA3047404A1 (en) | Compounds, compositions and methods of use | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| ME02747B (me) | Kristalni oblik gama ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| JP2016528179A (ja) | 製造方法及びｍｄｍ２阻害剤の結晶形 | |
| JP2009534373A5 (OSRAM) | ||
| PT2651890E (pt) | Derivados de estrigolactama e sua utilização como reguladores do crescimento das plantas | |
| JP2014510133A (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| ME02750B (me) | Kristalni oblik gama - d iv abradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| JP2005520819A5 (OSRAM) | ||
| JP2020502224A5 (OSRAM) | ||
| JP2016539136A5 (OSRAM) | ||
| EP3337485A1 (en) | Crystalline forms of ibrutinib | |
| JP2007519697A5 (OSRAM) | ||
| JP2005529084A5 (OSRAM) | ||
| JP2013511475A5 (OSRAM) | ||
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JP2020138960A5 (OSRAM) | ||
| WO2005085199A1 (en) | Novel polymorphs of etoricoxib | |
| JP2016510767A5 (OSRAM) | ||
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| JP2019529481A5 (OSRAM) |